People: Nanosphere Inc (NSPH.O)

NSPH.O on Consolidated Issue listed on NASDAQ Global Market

1.83USD
17 Apr 2014
Price Change (% chg)

$-0.02 (-1.08%)
Prev Close
$1.85
Open
$1.90
Day's High
$1.92
Day's Low
$1.83
Volume
472,488
Avg. Vol
722,140
52-wk High
$4.49
52-wk Low
$1.68

Search Stocks

Summary

Name Age Since Current Position

Sheli Rosenberg

2013 Chairman of the Board

Michael McGarrity

50 2013 President, Chief Executive Officer, Director

J. Roger Moody

45 Chief Financial Officer, Vice President - Finance & Administration, Treasurer, Secretary

Kenneth Bahk

39 2013 Chief Strategy Officer

Gene Cartwright

59 2013 Director

Erik Holmlin

2013 Director

Andre de Bruin

66 2005 Independent Director

Lorin Randall

69 2008 Independent Director

Michael Ward

2013 Independent Director

Biographies

Name Description

Sheli Rosenberg

Ms. Sheli Z. Rosenberg is the Chairman of the Board of Nanosphere, Inc. Ms. Rosenberg previously served as a director of the Company from 2002 to 2012. Ms. Rosenberg is currently Of Counsel at Skadden, Arps, Slate, Meagher & Flom LLP. Ms. Rosenberg is the retired chief executive officer, president and vice chairwoman of Equity Group Investments, Inc. She joined Equity Group Investments, Inc. in 1980 as General Counsel. She sits on the boards of three New York Stock Exchange corporations: Equity LifeStyle Properties, Inc., Strategic Hotels and Resorts, Inc. and Ventas, Inc.

Michael McGarrity

Mr. Michael K. McGarrity serves as President, Chief Executive Officer, Director of Nanosphere Inc. Mr.McGarrity joined Nanosphere in 2005 as Chief Marketing Officer. Mr. McGarrity, who has more than 18 years of sales and marketing experience in the medical device industry, joined Nanosphere after 13 years with Stryker Corporation. At Stryker, he served in leadership roles in marketing and strategic development, most recently as vice president of marketing for Stryker Instruments, where he also had executive general management responsibility for a newly created business focused on interventional pain management. Mr. McGarrity is a graduate of the University of Notre Dame and began his career in commercial banking in Chicago.

J. Roger Moody

Mr. J. Roger Moody, Jr., serves as Chief Financial Officer, Vice President - Finance & Administration, Treasurer, Secretary of Nanosphere Inc. Mr.Moody joined Nanosphere in 2007 as Chief Financial Officer and Vice President of Finance & Administration. He also serves as the Company’s Treasurer and Secretary. Mr.Moody has more than 20 years of experience in finance, corporate development and operations for high growth healthcare and technology companies. Previously, Mr. Moody spent six years at Medsn, a medical education company where he began as chief financial officer and was promoted to chief operating officer where he led Medsn’s United States and off-shore operations. Mr.Moody also served as chief financial officer and led corporate development for two private venture backed companies sold to strategic partners. Additionally, Mr. Moody provided mergers and acquisition and strategic advisory services to technology and healthcare companies for Volpe Brown Whelan & Company. Mr. Moody began his career at IBM. Mr.Moody received his B.S. from Syracuse University and his M.B.A. from the University of Chicago, Graduate School of Business.

Kenneth Bahk

Dr. Kenneth Bahk, Ph.D., is Chief Strategy Officer of Nanosphere, Inc. Dr. Bahk is a Director of Investments at Lurie Investments, focusing on investments in diagnostics and life sciences. Lurie Investments, together with its affiliates, is the holder ofNanosphere shares. Dr. Bahk currently serves on the board of directors of Aperion Biologics,Geneweave Biosciences and Viamet Pharmaceuticals. Dr. Bahk has been active in leadership positions for the premier diagnostic and molecular diagnostic organizations, and was Chair of Strategic Opportunities for the Association for Molecular Pathology, a committee charged with understanding key molecular diagnostic and pathology market drivers and trends. He is a member of the American Association of Clinical Chemistry, the American Society for Microbiology and the Association for Molecular Pathology. He received a Ph.D. in biochemistry and molecular biology and an MS in neurobiology and physiology from Northwestern University, and an MBA from the Kellogg School of Management.

Gene Cartwright

Dr. Gene Cartwright, Ph.D., has been appointed as Director of Nanosphere, Inc., effective June 20, 2013. Dr. Cartwright was CEO of Omnyx, LLC, a joint venture between GE and the University of Pittsburgh Medical Center, from 2008 to 2012. From 2005 to 2008, Dr. Cartwright served as President of Molecular Diagnostics for GE Healthcare with a focus on expanding GE’s presence in molecular diagnostics and blood testing through acquisitions. From 2001 to 2005, Dr. Cartwright was the Divisional Vice President and General Manager of Molecular Diagnostics for Abbott Diagnostics. While at Abbott, he oversaw development of Abbott’s current molecular diagnostics platform, the m2000, and its key infectious disease assays, including HIV, HCV, HBV and CT/GC. Dr. Cartwright received a Ph.D. in Chemistry from Stanford University, a Masters of Management from Northwestern University and a B.A. in Chemistry from Dartmouth College.

Erik Holmlin

Dr. Erik Holmlin, Ph.D., has been appointed as Director of Nanosphere, Inc., effective June 20, 2013. Dr. Holmlin is currently President and Chief Executive Officer of BioNano Genomics Inc., a commercial-stage company with a proprietary platform for genome mapping based on single molecule detection. From February 2010 to February 2011, Dr. Holmlin was an Entrepreneur in Residence at Domain Associates, LLC, a life sciences-dedicated venture capital firm, where one of his assignments was the role of President and Chief Executive Officer of GenVault Corporation, a provider of systems used for managing DNA collections. From July 2008 to November 2009 Dr. Holmlin was the Chief Commercial Officer of Exiqon A/S. In 2001, Dr. Holmlin led the formation of GeneOhm Sciences, Inc., a molecular diagnostics company that brought the first rapid tests for healthcare-associated infection (HAI) to market. In 2006, following GeneOhm’s acquisition by Becton Dickinson, Dr. Holmlin served as Vice President of Marketing and Development for Becton Dickinson Diagnostics until July 2008. Dr. Holmlin holds a Ph.D. in Chemistry from California Institute of Technology, MBA degrees from the Haas School of Business at UC Berkeley and the Columbia University School of Business and an AB degree in Chemistry from Occidental College.

Andre de Bruin

Mr. André De Bruin is Independent Director of Nanosphere Inc. Mr. de Bruin has more than 35 years of global healthcare industry experience spanning the bio-pharmaceutical, medical device and diagnostics markets. Most recently, Mr. de Bruin was the founder and chief executive officer of DuraPorts Inc., a manufacturer of steel and fabric structures. He also serves on the board of Directors of NxThera Inc., a medical device company based in St. Paul, MN, where he is Chairman of the Board. Prior to his retirement in 2004 as executive chairman of Quidel Corporation’s board of directors, Mr. de Bruin served as the company’s chief executive officer from 1998 until 2001. He was president and chief executive officer of Somatogen and was elected chairman in 1996. Prior to joining Somatogen, Mr. de Bruin was chairman, president and chief executive officer of Boehringer Mannheim Corporation, a global healthcare concern subsequently acquired by Hoffman-La Roche. Past experience includes advisory services for Ferrer, Freeman and Company, LLC and various boards of directors. Mr. de Bruin graduated from the University of Potchefstroom in South Africa, where he earned a B.S. in finance, economics and business.

Lorin Randall

Mr. Lorin Jeffry Randall is Independent Director of Nanosphere Inc. He has served as a member of Company's board of directors and the chairman of the audit committee since 2008. Mr. Randall is a financial consultant and also serves on the boards of the following healthcare companies: Tengion, Inc., Athersys, Inc. and Acorda Therapeutics, Inc. Mr. Randall previously served as senior vice president-chief financial officer of Eximias Pharmaceutical Corporation, a development stage provider of oncology therapeutics. Mr. Randall held the same position at i-STAT Corporation, a manufacturer of medical diagnostic devices, which was acquired by Abbott Laboratories in 2004. His career also includes senior management positions at CFM Technologies, a semiconductor manufacturing equipment company; Greenwich Pharmaceutical Corporation, a development stage provider of immune system disease therapeutics; and Surgilase, a provider of surgical lasers to hospitals and clinics. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.

Michael Ward

Mr. Michael J. Ward is Independent Director of Nanosphere, Inc. Mr. Ward joined Lurie Investments, Inc. in 2009 as a Vice President and is currently a Director, responsible for managing investment activities. Lurie Investments, Inc. beneficially owns 74,324 shares of the Company’s common stock and certain of its affiliates (such affiliates, together with Lurie Investments, Inc., being the “Lurie Entities”) beneficially own an aggregate of 14,650,413 shares of the Company’s common stock. Prior to joining Lurie Investments, Inc., Mr. Ward gained over 15 years of investment banking experience at Credit Suisse, Prudential Securities, Dresdner Kleinwort Wasserstein, BMO and Leerink Swann. Mr. Ward is a member of the board of directors of CytoPherx, Inc., an acute renal failure-focused therapeutic medical device company based in Ann Arbor, MI, and Discera, Inc., a MEMS (micro-electrical mechanical system) products company based in San Jose, CA.

Basic Compensation

Name Fiscal Year Total

Sheli Rosenberg

--

Michael McGarrity

637,900

J. Roger Moody

303,966

Kenneth Bahk

--

Gene Cartwright

--

Erik Holmlin

--

Andre de Bruin

--

Lorin Randall

--

Michael Ward

--
As Of 30 Dec 2012
Search Stocks